title: Treatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies.
authors.affiliation: Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Division of Immunology and Allergy, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
authors.forename: Lakiea S
authors.initials: LS
authors.lastname: Wright
authors.affiliation: Division of Immunology and Allergy, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: wanda.phipatanakul@childrens.harvard.edu.
authors.forename: Wanda
authors.initials: W
authors.lastname: Phipatanakul
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D002648:Child; D016207:Cytokines / Q000378:metabolism; D018450:Disease Progression; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods*; D000069444:Omalizumab / Q000627:therapeutic use*; D058408:Th1-Th2 Balance
chemical_list: D018926:Anti-Allergic Agents; D000911:Antibodies, Monoclonal; D016207:Cytokines; D000069444:Omalizumab; D007073:Immunoglobulin E